Kevin Starr - Global Blood Director
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
Director
Mr. Kevin P. Starr is Director of the company. since May 2012. In April 2007 Mr. Starr cofounded Third Rock Ventures where he remains a partner. From January 2003 to March 2007 Mr. Starr undertook a number of entrepreneurial endeavors in the life science and entertainment industries. From December 2001 to December 2002 Mr. Starr served as chief operating officer of Millennium Pharmaceuticals Inc. He also served as Millenniums chief financial officer from December 1998 to December 2002. Mr. Starr currently serves on the board of directors of Sage Therapeutics Inc. Agios Pharmaceuticals Inc. Alnylam Pharmaceuticals Inc. PanOptica Inc. MyoKardia Inc. Afferent Pharmaceuticals Inc. and Zafgen Inc. Mr. Starr received an M.S. in corporate finance from Boston College and a B.S.B.A. in mathematics and business from Colby College. Mr. Starrs qualifications to serve on our board of directors include his executive management roles with responsibility over key financial and business planning functions and experience in the formation development and business strategy of multiple startup companies in the life sciences sector. since 2012.
| Age | 51 |
| Tenure | 12 years |
| Phone | 650 741-7700 |
| Web | www.globalbloodtx.com |
Kevin Starr Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kevin Starr against Global Blood stock is an integral part of due diligence when investing in Global Blood. Kevin Starr insider activity provides valuable insight into whether Global Blood is net buyers or sellers over its current business cycle. Note, Global Blood insiders must abide by specific rules, including filing SEC forms every time they buy or sell Global Blood'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kevin Starr over three months ago Sale by Kevin Starr of 35000 shares of Sage Therapeutic |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| KlausPeter Mueller | Parker Hannifin | 74 | |
| Brett Harvey | Barrick Gold Corp | 67 | |
| Robert Bohn | Parker Hannifin | 66 | |
| Given Sibiya | Harmony Gold Mining | 52 | |
| Mashego Mashego | Harmony Gold Mining | 45 | |
| Candy Obourn | Parker Hannifin | 69 | |
| Karl Voltaire | Barrick Gold Corp | 63 | |
| Wolfgang Schmitt | Parker Hannifin | 72 | |
| Brian Greenspun | Barrick Gold Corp | 73 | |
| Graham Clow | Barrick Gold Corp | 66 | |
| Pablo Marcet | Barrick Gold Corp | 53 | |
| Karabo Nondumo | Harmony Gold Mining | 43 | |
| Eugene Zuriff | One Liberty Properties | 80 | |
| Michael Price | Eldorado Gold Corp | 63 | |
| Edward Gellert | One Liberty Properties | 53 | |
| Norborne Cole | Barrick Gold Corp | 73 | |
| James Verrier | Parker Hannifin | 57 | |
| Fikile Buck | Harmony Gold Mining | 60 | |
| Steven Shapiro | Barrick Gold Corp | 65 | |
| Gustavo Cisneros | Barrick Gold Corp | 74 | |
| Mavuso Msimang | Harmony Gold Mining | 79 | |
Management Performance
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
| Michael Bonney, Director | ||
| Stephanie Yao, IR Contact Officer | ||
| Myesha Lacy, IR Contact Officer | ||
| Mark Perry, Independent Director | ||
| Jeffrey Farrow, CFO | ||
| Myesha Edwards, IR Contact Officer | ||
| Philip Pizzo, Director | ||
| Glenn Pierce, Director | ||
| Willie Brown, Independent Director | ||
| Wendy Yarno, Director | ||
| Kevin Starr, Director | ||
| Hing Sham, Senior Vice President - Chemistry | ||
| Scott Morrison, Director | ||
| Deval Patrick, Independent Director | ||
| Tricia Suvari, Chief Legal Officer | ||
| Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
| David Johnson, Chief Commercial Officer | ||
| Charles Homcy, Director | ||
| Dawn Svoronos, Director | ||
| Ted Love, President CEO, Director | ||
| Eleanor Ramos, Chief Medical Officer | ||
| John Schembri, Vice President of Finance and Administration | ||
| Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |